Acting on the evidence
An educational programme for General Practice developed by international experts – Dr Lawrence Leiter and Dr Subodh Verma (Canada)
WHAT WILL YOU GAIN…
Participation in this fully accredited CPD programme gives you the opportunity to learn how:
- To interpret latest data on cardiovascular protection
- Differentiate cardiovascular outcome trial results practically to identify at-risk patients in your practice
- The benefits and risks of SGLT-2 inhibitor therapy
- To understand the renal benefits of SGLT-2 inhibitors and apply this therapy in your practice
WHAT WILL YOU LEARN…
![]() |
![]() |
|
Dr Lawrence A Leiter Division of Endocrinology and Metabolism St Michael’s Hospital Professor of Medicine and Nutritional Sciences, University of Toronto, Toronto, ON, Canada. |
Dr Subodh Verma Division of Cardiac Surgery St Michael’s Hospital Professor of Surgery and Pharmacology & Toxicology University of Toronto, Toronto, ON, Canada Canada Research Chair in Cardiovascular Surgery |
OUR LEARNING MODULES
EARN 15 CPD points by completing this programme
ACT 1: Cardiovascular and renal protection in diabetes »
ACT 2: Cardiovascular outcome trials in diabetes »
ACT 3: Renal protection in diabetes »
ACT 4: Review of renal therapies prior to SGLT-2 inhibitor therapy »
ACT 5: Renal benefits of SGLT-2 inhibitors in diabetes »
ACT 6: SGLT-2 inhibitors and safety »
Each module provides knowledge and expert comment
Supported by an unrestricted grant